GS
MRNA icon

GTS Securities’s Moderna MRNA Stock Holding History

GTS Securities’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,737
Closed -$616K – 1476
2025
Q1 		$616K Buy
+21,737
New +$771K 0.03% 589
2024
Q4 		– Sell
-102,159
Closed -$6.83M – 3016
2024
Q3 		$6.83M Buy
102,159
+59,665
+140% +$5.48M 0.01% 702
2024
Q2 		$5.05M Sell
42,494
-59,412
-58% -$7.52M 0.01% 855
2024
Q1 		$10.9M Sell
101,906
-40,154
-28% -$4.05M 0.02% 467
2023
Q4 		$14.1M Sell
142,060
-13,047
-8% -$1.1M 0.02% 465
2023
Q3 		$16M Buy
155,107
+38,023
+32% +$4.24M 0.03% 402
2023
Q2 		$14.2M Buy
+117,084
New +$15.6M 0.45% 51

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GTS Securities's MRNA Position: Q2 2025 in Review

GTS Securities sold out of Moderna (MRNA) in Q2 2025, closing a stake of 21,737 shares — an estimated $616K sold.

GTS Securities first reported a position in MRNA in Q2 2023 and held it in 7 quarters. The position peaked at $16M in Q3 2023. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

  • GTS Securities reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
  • GTS Securities sold 21,737 Moderna shares in Q2 2025, an estimated $616K.
  • GTS Securities first reported a position in Moderna in Q2 2023 and held it in 7 quarters.
  • GTS Securities's Moderna position peaked at $16M in Q3 2023.
  • 674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on GTS Securities's 13F filing for Q2 2025, filed 8 Aug 2025.